Business Desk :
Beximco Pharmaceuticals Limited on Monday announces it has received US Food and Drug Administration (FDA) approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia andartrial fibrillation.
This is company’s 8th Abbreviated New Drug Application (ANDA) successfully approved for the US market since the company’s oral solid dosage facility was approved by the US FDA in June 2015.The company expects to launch the product through its US distribution partner in due course, said a press rfelease.
“This approval is another important step in building and strengthening our presence in the US market. We continue to leverage our core strengths in R&D and manufacturing to develop and deliver specialisedgeneric products, not only in the US, but also in a global setting,” Nazmul Hassan Papon, Managing Director of Beximco Pharmaceuticals, said regarding the issue.
Beximco Pharmaceuticals Limited on Monday announces it has received US Food and Drug Administration (FDA) approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia andartrial fibrillation.
This is company’s 8th Abbreviated New Drug Application (ANDA) successfully approved for the US market since the company’s oral solid dosage facility was approved by the US FDA in June 2015.The company expects to launch the product through its US distribution partner in due course, said a press rfelease.
“This approval is another important step in building and strengthening our presence in the US market. We continue to leverage our core strengths in R&D and manufacturing to develop and deliver specialisedgeneric products, not only in the US, but also in a global setting,” Nazmul Hassan Papon, Managing Director of Beximco Pharmaceuticals, said regarding the issue.
